HeyJaredAriela Katz
- Indexed articles, last 90 days
- 6
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Sep 10, 2026
Latest articles
IMS 2026: Linvoseltamab May Yield Durable Responses in High-Risk Smoldering MM (opens the original)
Read excerpt
Updated data from the phase 2 LINKER-SMM1 study (NCT05955508) demonstrated single-agent, fixed-duration linvoseltamab had high rates of response in patients with high-risk smoldering multiple myeloma (HR-SMM), with a manageable safety profile, according to a poster presentation at the 23rd International Myeloma Society Annual Meeting. Prior research has shown that early intervention for patients with HR-SMM can delay or prevent disease progression to active multiple myeloma (MM), but there are l
IMS 2026: Linvoseltamab May Yield Durable Responses in High-Risk Smoldering MM - Oncology Nurse Advisor (opens the original)
Read excerpt
Updated data from the phase 2 LINKER-SMM1 study (NCT05955508) demonstrated single-agent, fixed-duration linvoseltamab had high rates of response in patients with high-risk smoldering multiple myeloma (HR-SMM), with a manageable safety profile, according to a poster presentation at the 23rd International Myeloma Society Annual Meeting. Prior research has shown that early intervention for patients with HR-SMM can delay or prevent disease progression to active multiple myeloma (MM), but there are l
BRUIN CLL-313 and -314: Pirtobrutinib Demonstrates Safety, Efficacy in Treatment-Naïve CLL/SLL - Oncology Nurse Advisor (opens the original)
Read excerpt
Pirtobrutinib yields high responses and improves survival in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to a pooled data analysis presented at the Society of Hematology Oncology 2026 Annual Meeting. Pirtobrutinib is approved globally for patients with CLL/SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor (BTKi). In this study, pooled data from the BRUIN CLL-313 and BRUIN CLL-314 trials (Clinical
Trial to Evaluate Bexobrutideg vs Pirtobrutinib in R/R CLL/SLL (opens the original)
Read excerpt
Researchers are investigating the efficacy and safety of bexobrutideg compared with the Bruton tyrosine kinase inhibitor (BTKi) pirtobrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent BTKi treatment, according to a poster presentation at the Society of Hematology Oncology 2026 Annual Meeting. Bexobrutideg, a novel, highly selective small molecule protein degrader of both wild-type and mutant forms of BTK
BRUIN CLL-313 and -314: Pirtobrutinib Demonstrates Safety, Efficacy in Treatment-Naïve CLL/SLL (opens the original)
Read excerpt
Pirtobrutinib yields high responses and improves survival in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to a pooled data analysis presented at the Society of Hematology Oncology 2026 Annual Meeting. Pirtobrutinib is approved globally for patients with CLL/SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor (BTKi). In this study, pooled data from the BRUIN CLL-313 and BRUIN CLL-314 trials (Clinical
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.